A review of recent advances in the treatment of adults with complicated urinary tract infection.
Emanuele RandoFrancesca GiovannenzeRita MurriEmilio SaccoPublished in: Expert review of clinical pharmacology (2022)
Novel antimicrobial drugs are available in the clinicians' armamentarium. Selecting the optimal therapy for suitable patients may be challenging given the multifaceted group of cUTIs. Carbapenems use is widely increasing, the role of old β-lactam/β-lactamase inhibitors is constantly revised, and novel drugs lack real-life studies. Understanding the different ranges of the complexity of patients affected by cUTIs may help select the most suitable antibiotic for every single case. More multicentric observational studies targeting cUTIs are needed to elucidate the appropriate drug based on patient characteristics and presentations, providing stronger recommendations for cases encountered in everyday clinical practice.
Keyphrases
- end stage renal disease
- clinical practice
- newly diagnosed
- ejection fraction
- chronic kidney disease
- urinary tract infection
- prognostic factors
- peritoneal dialysis
- escherichia coli
- emergency department
- patient reported outcomes
- case report
- cancer therapy
- combination therapy
- smoking cessation
- replacement therapy
- adverse drug